


Supplemental Figure 1


A




Supplemental Figure 1. Gating strategy for ILC2s. (A) ILC2s were identified as CD45+, Lineage-, CD127+, CD90+, ICOS+. To confirm ILC2 identity, ILC2s were sorted according to the above gates and production of IL-5 (B) and IL-13 (C) was measured by ELISA after stimulation with IL-2 and/or IL-33.

Supplemental Figure 2


A



B



C



Supplemental Figure 2. Quantification of ILC2s. Gating strategy (A) and quantification of ST2⁺, CD25⁺, KLRG-1⁺, or CD25⁺KLRG-1⁺ ILC2s from mice treated with DT or PBS at the indicated time points from Figure 5A and infected with HMPV (B) or influenza (C). #p<0.05, ##p<0.01, One-way ANOVA with Tukey's post-hoc comparison. N=4 mice/group, pooled from 2 independent experiments.